In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Elidel (Valeant)
- INDICATIONS: Second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis
- CLASS: Immunomodulator, Macrolactam
- HALF-LIFE: N/A
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Alcohol, Alefacept, Aprepitant, Azacitidine, Betamethasone, Cabazitaxel, Calcium channel blockers, Cimetidine, Conivaptan, CYP3A4 inhibitors, Darunavir, Delavirdine, Denileukin, Docetaxel, Efavirenz, Erythromycin, Fingolimod, Fluconazole, Gefitinib, Immunosuppressants, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Leflunomide, Lenalidomide, Oxaliplatin, Pazopanib, Pemetrexed, Pralatrexate, Telithromycin, Temsirolimus, Triamcinolone, Voriconazole
- See adverse reactions attributed to class:
LONG-TERM SAFETY OF TOPICAL CALCINEURIN INHIBITORS HAS NOT BEEN ESTABLISHED.
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
